 |
|
Joseph Schlessinger
William H. Prusoff Professor and Chair of Pharmacology
Joined Yale in 2001
Education:
| 1968 | B.Sc., Chemistry and Physics, Magna Cum Laude, The Hebrew University, Jerusalem. |
| 1969 | M.Sc. in Chemistry, Magna Cum Laude, The Hebrew University, Jerusalem. |
| 1974 | Ph.D. Thesis on "Study of Chemical and Biological Systems by Circular Polarization of Fluorescence," Department of Chemical Physics, The Weizmann Institute of Science, Rehovot, Israel. |
Awards:
1973 Michael Landau Prize for Ph.D. Thesis
1980 Sara Leedy Prize
1982 Elected to EMBO
1983 Hestrin Prize
1984 Levinson Prize
1995 The Drew-Ciba Prize (with G. Blobel and A. Levine)
1995 Antoine Lacassagne Prize
1999 The Distinguished Service Award, Miami Nature Biotechnology
1999 Honorary Member, The Japanese Biochemical Society
2000 Elected to the National Academy of Science
2000 The Taylor Prize (with T. Hunter and T. Pawson)
2001 Elected to the American Academy of Arts and Sciences
2002 Honorary Doctor of Philosophy, Honoris Causa, University of Haifa
2004 Elected to the European Academy of Sciences
2005 Elected to the Institute of Medicine of the National Academies
2006 Elected as a foreign member of the Russian Academy of Sciences
2006 Dan David Prize
2008 Elected as a foreign member of the Croatian Academy of Science
2009 Medal of Danica Hrvatska Order, Republic of Croatia
Research Interests:
Tyrosine phosphorylation
plays a critical role in the control of many cellular processes including
cell proliferation, differentiation, metabolism, as well as cell survival
and migration. Receptor tyrosine kinases undergo ligand dependent dimerization
which activates their intrinsic protein tyrosine kinase (PTK) domains. We
have determined the crystal structure of Stem cell factor (SCF) and fibroblast
growth factor (FGF), two ligands of receptor tyrosine kinases. In addition,
we have determined the crystal structure of FGF in complex with the extracellular
ligand binding domain of FGF-receptor (FGFR) and with a heparin sulfate
oligosacchride. The structure of the ternary FGF/heparin/FGFR complex provides
a molecular view of how FGF acts in concert with heparin to induce the dimerization
and activation of FGF-receptors. We have also determined the crystal structure
of the catalytic PTK domain of FGFR in complex with an ATP analogue or in
complex with specific PTK inhibitors of FGFR activity and function. These
structures enabled the development of new specific inhibitor for PTKs that
are currently being tested in clinical trials.
Receptor tyrosine kinases undergo ligand-dependent dimerization,
which activates their intrinsic protein tyrosine kinase activity resulting
in autophosphorylation and subsequent interaction and recruitment of multiple
cellular target proteins. The phosphorylated tyrosine residues together
with their immediate flanking sequences function as binding sites for signaling
molecules containing src homology 2 (SH2) domains. Many signaling proteins
carry SH2 domains plus one or more small protein modules such as SH3, PH,
PTB, WW or FYVE domains. These protein modules function as mediator of protein-protein
or protein-lipid interactions that are critical for signal transmission.
In addition to direct recruitment by RTKs, many signaling proteins are recruited
by an alternative mechanism involving a family of membrane linked docking
proteins such as FRS-2a, and b, IRS-1 and 2, and Gab-1 and 2, among many
others. Recruitment of signaling proteins by RTKs or by docking proteins
leads to activation of multiple signaling pathways resulting in stimulation
of a variety of cellular responses. The small adapter protein Grb2, for
example, is bound through its SH3 domains to short, proline-rich sequences
in the carboxy terminal tail of the guanine nucleotide-releasing factor
Sos. Interaction between Grb2 and Sos with tyrosine phosphorylated RTKs
or docking proteins results in translocation of Sos to the plasma membrane
allowing the exchange of GDP for GTP on Ras. The activated GTP-bound form
of Ras then starts a kinase cascade composed of Raf, MAPKK, and MAPK leading
to phosphorylation of prooncogene Jun on serine and threonine residues to
induce transcriptional activation. These and other signaling pathways that
are activated by RTKs regulate multiple cellular processes. Many cancers
and other diseases are caused by dysfunctions in RTKs or in components of
their intracellular pathways.
Reference Search:
Search for references on PubMed
|
|
|
Contact Information
Joseph Schlessinger
Department of Pharmacology
Yale University School of Medicine
333 Cedar Street
PO Box 208066
New Haven, CT 06520-8066
Courier Address:
333 Cedar Street, SHM B295
New Haven, CT 06520
Phone:
(203) 785-7395
Fax:
(203) 785-3879
Email:
Website:
|
|